Exelixis | EXEL - Spese Di Vendita E Di Amministrazione





Spese Di Vendita E Di Amministrazione Cambiamento Data
Acadia Pharmaceuticals USD 146.88M 1.69M 2026-09
Agios Pharmaceuticals USD 51.55M 13.09M 2026-06
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Amgen USD 1.68B 40M 2026-09
AstraZeneca USD 4.07B 1.73B 2026-09
Bayer EUR 4.02B 53M 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Cytokinetics USD 113.14M 8.75M 2026-09
Eisai JPY 120.4B 5.58B 2026-09
Eli Lilly USD 3.12B 305M 2026-09
Exelixis USD 154.56M 6.93M 2026-09
Genmab DKK 205M 39M 2026-06
Glaxosmithkline GBP 2.38B 264M 2026-09
Incyte USD 364.27M 12.54M 2026-09
Ionis Pharmaceuticals USD 154M 23.92M 2026-09
MacroGenics USD 7.9M 1.81M 2026-06
Merck USD 2.86B 25M 2026-09
Moderna USD 282M 66M 2026-09
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Novartis USD 3.08B 163M 2026-09
Pfizer USD 3.28B 132M 2026-09
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sanofi EUR 2.63B 140M 2026-06
Takeda JPY 271.71B 14.8B 2026-09
Ultragenyx Pharmaceutical USD 97M 9M 2026-09
Xencor USD 71.93M 5.61M 2026-09